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Abstract: Background: Plant-derived phytochemicals have been of emerging interest as anti-obesity
compounds due to their apparent effects on promoting reduced lipid accumulation in adipocytes.
Despite such promising evidence, little is known about the potential mechanisms behind their
anti-obesity effects. The aim of this study is to establish potential anti-obesity effects of the
phytochemical guggulsterone (GS). Methods: Mature 3T3-L1 adipocytes were treated with GS,
derived from the guggul plant native in northern India, to investigate its effects on mitochondrial
biogenesis and adipocyte “beiging.” Further, to explore the relationship between macrophages and
adipocytes, 3T3-L1s were treated with conditioned media from GS-treated RAW264.7 macrophages.
Markers of mitochondrial biogenesis and beiging were measured by western blot. Results: GS
treatment in adipocytes resulted in increased mitochondrial density, biogenesis (PGC1α and PPARγ),
and increased markers of a beige adipocyte phenotype (UCP1, TBX1, and β-3AR). This upregulation
in mitochondrial expression was accompanied by increases oxygen consumption. In GS-treated
macrophages, markers of M2 polarization were elevated (e.g., arginase and IL-10), along with
increased catecholamine release into the media. Lastly, 3T3-L1 adipocytes treated with conditioned
media from macrophages induced a 167.8% increase in UCP1 expression, suggestive of a role of
macrophages in eliciting an anti-adipogenic response to GS. Conclusions: Results from this study
provide the first mechanistic understanding of the anti-obesity effects of GS and suggests a role for
both direct GS-signaling and indirect stimulation of M2 macrophage polarization in this model.
Keywords: guggulsterone; obesity; 3T3-L1; beige adipocytes; RAW264.7; M2 polarization
1. Introduction
Obesity is a complex disease associated with a pathological expansion of white adipose tissue.
Adipose tissue has been traditionally classified into the energy-storing white adipose tissue and
energy-dissipating, thermogenic brown adipose tissue. In specific environmental conditions, such as
elevated beta-adrenergic signaling, white adipose tissue can upregulate mitochondrial biogenesis,
uncoupling protein-1 (UCP1) expression, and respiration [1]. This change in the metabolic potential has
been termed “beiging” both because of the browning in color of adipocytes in addition to a phenotype
that is more metabolically active than white adipose but not to the extent of brown adipose tissue.
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Increases in beiging have been demonstrated in rodents exposed to cold [2] and chemical agents [3],
which can increase metabolic rate, dispense excess energy, and promote weight loss (or protection
from weight gain). Due to the expansiveness of the white adipose depot over brown depots in obesity,
understanding how the process of beiging works and how it can be manipulated is a rapidly evolving
area of research.
Many plant-derived compounds have anti-obesity effects, and are reported to prevent
adipogenesis and promote lipolysis in both in vitro and in vivo models [4,5]. The specific mechanisms
that drive these responses, however, are not as well described. It has been hypothesized that
many phytochemicals may have the potential to induce transdifferentiation of adipocytes to a beige
phenotype [6]. For example, resveratrol is a potent activator of the sirtuins [7], which independently
upregulates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and
mitochondrial biogenesis [8]. Further, novel work has demonstrated that phytochemicals may
stimulate macrophage M2 polarization, which promotes the release of both anti-inflammatory
cytokines [9] and as hypothesized in the current study, catecholamines. Interestingly, recent work
has evidenced that macrophage M2 polarization may contribute to adipocyte beiging and energy
expenditure [10]. Pro-inflammatory macrophage infiltration into the adipose depot is a characteristic
of obesity [11,12]. Thus, conversion of resident macrophages to catecholamine-secreting cells may
promote localized beta-adrenergic signaling and induce beiging in adipose tissue [13,14]. Despite such
intriguing links, little work to date has explored the beiging potential of phytochemicals in either direct
or indirect methods of adipocyte beiging.
Guggulsterone (GS) is a bioactive phytochemical derived from the guggul plant. It is both
an agonist and antagonist for various steroid receptors and thus, has been suspected to have
beneficial effects in cancer [15] and cardiovascular disease prevention [16], and as an anti-obesity
compound. Previous work from our lab has shown that GS treatment in 3T3-L1 adipocytes can
impair differentiation and induce both lipolysis and apoptosis in mature adipocytes [17]. Further,
these beneficial effects on adipogenesis can be heightened with the addition of genistein in the
media [18]. In vivo, GS promotes a beneficial lipid profile in rats fed a high fat diet, along with an
improvement in glucose control [19]. Further, it has also been shown that GS can blunt weight gain in
rats by reducing food intake, suggesting the anti-obesity properties may be multifaceted [20]. GS is
an agonist for the bile acid receptors, which has been identified as a potential regulator of thyroid
hormone signaling [21]. As elevations of triiodothyronine (T3) induce an upregulation of UCP1,
it may be plausible that GS induces adipocyte beiging through modulating T3 synthesis. Further,
GS has anti-inflammatory properties in cultured macrophages [22]. Hence, GS may also function as a
beige adipogenic factor through indirect mechanisms involving M2-polarization. To our knowledge,
the efficacy of GS to stimulate beiging of adipocytes has yet to be investigated.
A recent set of studies demonstrated that 3T3-L1 adipocytes are a useful model of beiging [23].
In mature 3T3-L1 adipocytes, beta-adrenergic stimulation induces UCP1 upregulation and increases
cellular oxygen consumption by reducing coupling efficiency [24]. Utilizing this model, the current
study sought to determine if the anti-obesity phytochemical, GS, can promote mitochondrial biogenesis
and beiging in 3T3-L1 adipocytes. Furthermore, we investigated if this could be mediated through
direct stimulation of adipocytes and by indirect stimulation through macrophage M2 polarization and
catecholamine release. Findings from this study provide evidence that GS-treatment induces adipocyte
beiging through both direct stimulation of mitochondrial biogenesis and indirectly by the polarization
of macrophages that can signal to adipocytes and activate adrenergic pathways.
2. Materials and Methods
2.1. Cell Culture
Mouse embryo 3T3-LI preadipocytes were purchased from Zenbio (Research Triangle Park, NC,
USA) and RAW264.7 macrophages were purchased from America Type Culture Collection (Manassas,
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VA, USA). 3T3-L1 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM/F12) GlutaMAX
with 10% calf serum (CS; Thermo Fisher Scientific, Waltham, MA, USA), and 1% penicillin streptomycin
(PS; Sigma-Aldrich, St. Louis, MO, USA). 3T3-L1 cells were grown to confluence and induced to
differentiate using differentiation media I (DM I) containing DMEM/F12 GlutaMAX with 10% fetal
bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA), 1% PS, 5 µM dexamethasone
(Dexa), 1 mg/mL insulin, 0.5 mM 3-isobutyl-1-methylxanthine, and 1 µM rosiglitazone (Sigma-Aldrich,
St. Louis, MO, USA). Cells were maintained in DM I for 3 days followed by another 4–6 days in DM
II which contained DMEM/F12 GlutaMAX with 10% FBS, 1% PS, 1 mg/mL insulin, and 1 µM Dexa.
Media was changed every other day during the process of differentiation and by day 8, 90–95% of
cells were mature adipocytes with lipid droplets. Adipocyte-specific assays are described in the
following sections.
The murine monocytic cell line, RAW264.7, was cultured in Roswell Park Memorial Institute
media (RPMI; ThermoFisher Scientific, Waltham, MA, USA) complete with 10% FBS and 1% PS for
macrophage polarization experiments. After 95% confluency, RAW264.7 cells were treated with 0.1%
DMSO vehicle, (E)-guggulsterone (GS; Sigma-Aldrich, St. Louis, MO, USA) 6 µM or IL-4 20 ng/mL
(interleukin-4; R&D Systems, Minneapolis, MN, USA).
For conditioned media experiments, RAW264.7 cells were cultured in DMEM/F12 GlutaMAX
supplemented with 10% FBS and 1% PS. After 48 h of treatment with GS (6 µM) or IL-4 (20 ng/mL),
conditioned media was collected from RAW264.7 cells and transferred to mature 3T3-L1 adipocytes
for 24 h.
2.2. Lipid Quantification
Lipid droplets were stained in mature adipocytes treated with varying doses of GS (6–25 µM) or
0.1% DMSO vehicle control during the differentiation period using the AdipoRed™ reagent (Lonza
Inc., Walkersville, MD, USA) according to manufacturer’s protocol. The microplate was read using the
HT Synergy (BioTek, Winooski, VT, USA) microplate reader.
2.3. Cell Viability
Mature adipocytes and RAW264.7 macrophages were treated with GS or 0.1% DMSO vehicle
control for 24 and 48-h, respectively. Cell viability was measured after treatment using Prestoblue®Cell
Viability Reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s protocol.
Absorbance of metabolically active cells was measured one hour after incubation using an HT Synergy
microplate reader at 570 nm.
2.4. Mitochondrial Biogenesis
Mature 3T3-L1 adipocytes were treated with GS (25 µM), isoproterenol (10 µM), or 0.1% DMSO
vehicle control for 24 h and incubated with MitoTracker®Green FM (Thermo Fisher Scientific, Waltham,
MA, USA) according to manufacturer’s instructions. Mitochondrial activity was measured using the
HT Synergy microplate reader.
2.5. Oxygen Consumption
Mature adipocytes were treated with GS (25 µM) and isoproterenol (10 µM), or 0.1% DMSO
vehicle for 24 h. The Oxygen Consumption/Glycolysis Dual Assay Kit (Cayman Chemical, Ann Arbor,
MI, USA) was used to detect oxygen consumption following manufacturer’s protocols. Fluorescence
of the MitoXpress®Xtra reagent was measured using the HT Synergy microplate reader.
2.6. Immunoblot Analysis
Following treatment with GS for 24 or 48 h, cells were suspended with ice cold RIPA Lysis
and Extraction buffer, complete with protease and phosphatase inhibitors (Thermo Fisher Scientific,
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Grand Island, NY, USA). Whole cell lysate was prepared by centrifuging cells for 10 minutes at
13,300× g. Protein estimation was then determined using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific, Grand Island, NY, USA). Proteins were separated on discontinuous SDS 4–20%
polyacrylamide gels and transferred onto a polyvinylidene difluoride (PVDF) membrane using a
Trans-blot Turbo system (Bio-Rad, Hercules, CA, USA) and then blocked for one hour with Tris buffered
saline plus 0.1% Tween 20 (TBS-T) containing 5% bovine serum albumin (BSA). Following blocking,
blots were then incubated for one hour in TBS-T plus 5% BSA with primary antibodies. Blots were
incubated with secondary antibodies conjugated to IRDye 800 and developed using the Odyssey CLX
imaging system (LiCor Biosciences, Lincoln, NE, USA). Signal intensity was determined for each band
using the LiCOR imaging system software (Image Studio Ver. 5.2, LiCor Biosciences, Lincoln, NE,
USA). For each protein of interest, the density value was normalized to the corresponding density
of the loading control to obtain the integrated density values. These values were then normalized to
control samples run on the same gel.
Primary antibodies used were: anti-β-Actin (sc-47778; 1/10,000 dilution) from Santa Cruz
Biotechnology Inc. (Dallas, TX, USA). Anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase;
ab9484; 1/10,000 dilution), anti-UCP1 (ab10983; 1/2000 dilution), anti-liver-arginase-1 (ab124917;
1/2000 dilution), and anti-TBX1 (t-box transcription factor 1; ab18530; 1/2000 dilution) antibodies
were from Abcam (Cambridge, United Kingdom). Anti-β-3AR (β-3 adrenergic receptor; PA5-50914;
1/500 dilution) was from Thermo Fisher Scientific (Grand Island, NY, USA). Lastly, anti-α-Tubulin
(NB100-690; 1/10,000 dilution), anti-PPARγ (peroxisome proliferator-activated receptor-γ; NBP2-22106;
1/1,000 dilution), and anti-PGC-1α (peroxisome proliferator-activated receptor-γ coactivator 1-α;
NBP1-04676SS; 1/1000 dilution) antibodies were purchased from Novus Biologicals (Littleton, CO,
USA). Membranes were incubated in their respective primary antibody for 1 h at room temperature.
2.7. Catecholamine Assay
Following 48-h incubation with GS in RAW264.7 cells, the culture supernatant was removed to
quantify catecholamine release. Catecholamine levels were determined using ELISA according to
manufacturer’s instructions (Blue Gene for Life Science, Shanghai, China). The assay plate was read
on a HT Synergy microplate reader.
2.8. Interleukin-10 (IL-10) ELISA
Following 24-h incubation with GS, the culture supernatant was removed to quantify IL-10
secretion. IL-10 levels were determined using ELISA according to manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA). The assay plate was read on a HT Synergy microplate reader at
450 nm.
2.9. Data Analysis
All data was normalized to control and expressed as the mean ± S.E.M. Either t-tests or Dunnett’s
multiple comparisons test was used to determine difference between treatment groups and control
where appropriate. Statistical analysis and graphs were made using GraphPad Prism (version 6.07;
La Jolla, CA, USA). Statistically significant differences are defined at p < 0.05.
3. Results
3.1. GS inhibits Adipogenesis in 3T3-L1 Adipocytes
3T3-L1 preadipocytes were cultured with GS (6, 12.5, 25 µM) during the adipogenesis period
for 6 days. Both the 12.5 and 25 µM dose of GS reduced total lipid content in adipocytes following
treatment (55.1 ± 11.9%, p < 0.0001 and 80.2 ± 8.9%, p < 0.0001 respectively; Figure 1). The lowest dose
of GS (6 µM) did not significantly reduce lipid accumulation in mature 3T3-L1 adipocytes. These results
are in agreement with our previous findings on the anti-adipogenic effects of GS [16,17].
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Figure 1. Guggulsterone (GS) reduced lipid accumulation in 3T3-L1 adipocytes. GS treatment during 
the differentiation period in 3T3-L1 adipocytes reduces adipogenesis in a dose dependent manner. 
Data presented as mean ± SEM from n = 3–6 replicates per group. **** p < 0.0001 vs. control. 
3.2. Effect of GS on 3T3-L1 Viability and Apoptosis 
Mature 3T3-L1 adipocytes were cultured with GS (6, 12.5, 25 μM) for 24-hours. Following 
treatment, there was no impact of GS on cell viability (Figure 2A) or caspase-3 activation (Figure 2B), 
indicating that GS does not produce cytotoxic effects in adipocytes.  
 
Figure 2. GS treatment does not impact viability of 3T3-L1 adipocytes. GS treatment for 24 h in 
mature, 3T3-L1 adipocytes has no effect on cell viability (A) or apoptosis as measured by caspase 3 
(B). Data presented as mean ± SEM from n = 3–6 replicates per group. 
3.3. Effect of GS on Mitochondrial Biogenesis and Oxygen Consumption 
Mitochondria were quantified following a 24-hour treatment with GS through fluorescence 
intensity of Mitotracker staining. Mitochondrial density increased by 7.2 ± 2.3% (p < 0.05) at the 25 
μM dose (Figure 3A), which resulted in a significant upregulation of oxygen consumption compared 
to untreated cells (210 ± 23.9%, p < 0.001; Figure 3B). GS at 25 μM also increased the concentration of 
PGC1α (105.7 ± 22.2%, p < 0.05; Figure 3C) compared to control, DMSO-treated cells, and a small 
increase in PPARγ was observed, but did not reach significance (p = 0.07; Figure 3D). GS at the 6 μM 
Figure 1. Guggulsterone (GS) reduced lipid accumulation in 3T3-L1 adipocytes. GS treatment during
the differentiation period in 3T3-L1 adipocytes reduces adipogenesis in a dose dependent manner.
Data presented as mean ± SEM from n = 3–6 replicates per group. **** p < 0.0001 vs. control.
3.2. Effect of GS on 3T3-L1 Viability and Apoptosis
Mature 3T3-L1 adipocytes were cultured with GS (6, 12.5, 25 µM) for 24-h. Following treatment,
there was no impact of GS on cell viability (Figure 2A) or caspase-3 activation (Figure 2B), indicating
that GS does not produce cytotoxic effects in adipocytes.
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Figure 2. GS treatment does not impact viability of 3T3-L1 adipocytes. GS treatment for 24 h in mature,
3T3-L1 adipocytes has no effect on cell viability (A) or apoptosis as measured by caspase 3 (B). Data
presented as mean ± SEM from n = 3–6 replicates per group.
3.3. Effect of GS on Mitochondrial Biogenesis and Oxygen Consumption
Mitochondria were quantified following a 24-h treatment with GS through fluorescence intensity
of Mitotracker staining. Mitochon ria density increased by 7.2 ± 2.3% (p < 0.05) at the 25 µM
dose (F gure 3A), which resulted in a significant upregulation of oxygen consumption comp red to
untreated cells (210 ± 23.9%, p < 0.001; Figure 3B). GS at 25 µM also increased the c nce tration of
PGC1α (105.7 ± 22. %, p < 0.05; Figure 3C) compared to co t ol, DMSO-treated c lls, and a small
increase in PPARγ was observed, but did not rea h signifi a ce (p = 0.07; Figure 3D). GS at the 6
µM conc ntration failed t increase PGC1α, however the dose increased PPARγ compared to con rol
(22.9 ± 6.1%; p < 0.01).
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Figure 3. GS treatment in 3T3-L1 adipocytes induces mitochondrial biogenesis. GS treatment 
increases mitochondrial density (20× objective) (A), oxygen consumption rate (B), and markers of 
mitochondrial biogenesis (C and D). Data presented as mean ± SEM from n = 3–6 replicates per group. 
# p < 0.10, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control. Abbreviations: isoproterenol (ISO), peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), peroxisome proliferator-
activated receptor gamma (PPARγ).  
3.4. GS-Induced Effects on Markers of Beige Adipocytes 
Markers of beiging, notably the presence of UCP1, TBX1, and β-3AR were quantified in GS-
treated cells. 25 μM GS increased UCP1 (106.8 ± 23.8%, p < 0.05; Figure 4A) and TBX1 (81.6 ± 3.3%, p 
< 0.05; Figure 4B) compared to the control. β-3AR was upregulated with treatment of both 6 μM and 
25 μM (131.2 ± 24.7% and 164.3 ± 21.4%, respectively; Figure 4C) compared to control-treated cells. 
This increase in markers of beiging was to a similar extent to what was observed when mature 
adipocytes were cultured with the beta agonist, isoproterenol for 24 h.  
Figure 3. GS treatment in 3T3-L1 adipocytes induces mitochondrial biogenesis. GS treatment increases
mitochondrial density (20× objective) (A), oxygen consumption rate (B), and markers of mitochondrial
biogenesis (C and D). Data presented as mean ± SEM from n = 3–6 replicates per group. # p < 0.10,
* p < 0. 5, ** < 0.01, *** p < 0.001 vs. contr l. Abbreviat ons: isoproterenol ), peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), peroxisome pr lif rator-activated
recep or gamma (PPARγ).
3.4. GS-Induced Effects on Markers of Beige Adipocytes
Markers of beigin , otably the pr sence of UCP1, TBX1, and β-3AR were quantified in GS-treated
cells. 25 µM GS increased UCP1 (106.8 ± 23.8%, p < 0.05; Figure 4A) and TBX1 (81.6 ± 3.3%, p < 0.05;
Figure 4B) compared to th c ntrol. β-3AR was upregulated with treatment of 6 µM and
25 µM (131.2 ± 24.7% and 164.3 ± 21.4%, respecti ) co pared to control-treated cells.
This increas in markers of beiging was to a similar extent t t served when mature
adipocytes were cultured with the beta agonist, isoproterenol for 24 h.
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Figure 5. GS treatment in RAW264.7 macrophages induces M2 polarization. GS treatment induces an 
M2-like phenotype in macrophages as suggested by arginase activation (A), catecholamine release 
Figure 4. GS treatment increase markers of beiging in 3T3-L1 a i S treat ent upregulates
marke s of beigin , including UCP1 (A), TBX1 (B), and β-3AR (C) proteins. Data presented as mean ±
SEM from n = 4 replicates per group. * p < 0. 5, ** p < 0.0 1 vs. c r iations: isoproterenol
(ISO), uncoupling protein 1 (UCP1), glyceraldehyde 3-phos enase (GAPDH), T-box
protein 1 (TBX1), β-3 adren rgic rec ptor (β-3AR).
3.5. Effect of GS on M2 Polarization of Macrophages
To determine if GS indirectly promotes beiging in a i r gh acrophage M2
polarization, viability was first deter i S-treated RAW264.7 macrophages following 24 h
of treat e t t shown). GS impaired viability at 12.5 µM (18.0 ± 3.0%, p < 0.001) and 25 µM
(25.6 ± 3.4%, p < 0.0001), ther fore, GS 6 µM was chosen as an optimal concentration.
The M2 polarization of the RAW264.7 macrophage cell line as then assessed following GS
treatment. RAW264.7 macrophages were then cultured with 6 µM GS or IL-4 for 48 h to determine
if treatment resulted in an M2-like phenotype. Both IL-4 control (578.3 ± 68.5%, p < 0.01) and GS
treatment (608 ± 91.7%; p < 0.01) upregulated arginase expression (Figure 5A). Along with arginase
upregulation, treatment sufficiently stimulated catecholamine release at approximately the same
level for both IL-4 control (54.6 ± 5.4%, p < 0.001) and 6 µM GS (51.5 ± 8.0%, p < 0.01; Figure 5B).
Similarly, IL-10 release in the media was also upregulated with 6 µM GS treatment compared to control
(49.9 ± 9.8%, p <0 .01; Figure 5C). Together, these data suggested that GS induced M2 activation of
macrophages at the same extent to that of IL-4 treatment.
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Figure 5. GS treatment in RAW264.7 macrophages induces M2 polarization. GS treatment induces an
M2-like phenotype in macrophages as suggested by arginase activation (A), catecholamine release into
the media (B), and release of IL-10 (C). Data presented as mean ± SEM from n = 3–6 replicates per
group. * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: interleukin 4 (IL-4).
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3.6. Role of M2 Macrophage Polarization on GS-Induced on Adipocyte Beiging
Lastly, in an additional experiment, conditioned media from GS-treated RAW264.7 macrophages
were plated onto mature 3T3-L1 adipocytes. UCP1 was upregulated in the adipocytes (170.7 ± 54.1%;
p < 0.01) compared to untreated RAW264.7 conditioned media (Figure 6A). This upregulation was to a
similar extent of IL-4-stimulation (185.5 ± 65.8%). PGC1α was increased by 15.8 ± 8.0% (p = 0.06) by
indirect GS treatment and 14.8 ± 2.1% (p < 0.01) by indirect IL-4 treatment compared to un-treated
conditioned media (Figure 6B). Lastly, a marker of beige adipocytes was also analyzed following 24 h
of conditioned media treatment; TBX1 was increased with both GS (771.0 ± 224.7%; p < 0.01) and IL-4
(1047 ± 322.1%; p < 0.05) conditioned media (Figure 6C).
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GS and IL-4 treatment upregulate UCP1 (A), PGC1α (B), and TBX1 (C) expression through direct
stimulations in 3T3-L1 adipocytes and indirectly via con itione edia from RAW264.7-treated
macrophages. Data presented as mean ± SEM from n = 3–4 re l er group. # p < 0.10, * p < 0.05,
** p < 0.01 vs. control. Abbreviations: Uncoupling protein 1 (UCP1), interleukin 4 (IL-4), peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), T-box protein 1 (TBX1).
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4. Discussion
The current study expands on the mechanistic understanding of the anti-obesity effects of GS in
adipocytes in vitro. Mature 3T3-L1 adipocytes treated with GS demonstrated increased markers of
mitochondrial biogenesis and UCP1 expression, indicative of an induction of a beiging phenotype.
As adipose tissue contains macrophages, in addition to adipocytes, this study also explored the effects
of GS on RAW264.7 cells. Macrophages treated with GS increased arginase expression, stimulated
the secretion of IL-10, an inflammatory cytokine, and upregulated catecholamine release into the
media indicative of M2 polarization. Further, conditioned media from GS-treated macrophages were
sufficient enough to induce UCP1 expression in adipocytes.
GS has been proposed to be an anti-obesity phytochemical. In vitro treatment of GS results in
reduced lipid accumulation, partly by inducing apoptotic pathways [25] and reducing adipogenic
signaling in differentiating adipocytes [16,17]. Herein, we demonstrate that a novel anti-obesity
property of GS is the induction of beiging. GS shares a structural similarity to many of the steroid
hormones and has both agonistic and antagonistic capabilities on a number of steroid receptors
including the Takeda G-protein-coupled receptor 5 (TGR5) bile acid receptor, estrogen receptor, and the
progesterone receptor. Hence, it is likely that the reason that GS has been suggested to target diseases
ranging from cancer to cardiometabolic health is attributable to its ability to interact with a broad
spectrum of steroid receptors. Sex hormones have been hypothesized to influence the thermogenic
potential of brown adipose tissue, with both estrogen and progesterone having positive effects on UCP1
expression [26]. Unsurprisingly, activation of estrogen receptor alpha in 3T3-L1 adipocytes induces
expression of UCP1 and TBX1 through phosphorylation of AMP-activated protein kinase (AMPK) [27],
which is a critical sensor of energy balance and an upstream regulator of UCP1 [28]. Further, activation
of the TGR5 bile acid receptor can independently induce thermogenesis in brown adipose tissue [21,29].
TGR5 signaling upregulates DIO2 expression, which may increase the UCP1 expression necessary
for thermogenesis. Together, this suggests that GS may induce beiging in adipocytes through several
potential signaling cascades, which could have been responsible for the upregulation of UCP1 and
oxygen consumption observed in the current study. However, this also makes it difficult to understand
the specific signaling mechanisms by which GS may be working through in adipocytes.
While we are unable to explain how GS directly induces a beige phenotype in the 3T3-L1 adipocyte,
we sought to explore if signals from other peripheral cell types in adipose tissue may influence this
phenomenon. Specifically, macrophages can be found in concentrations of upwards of 40% of the
cell types in adipose tissue from obese subjects [11] and thus, makes macrophages an important
target for anti-obesity compounds. A small subset of studies exist that investigate the effects of GS
on macrophages. Perhaps most relevant, a recent study by Che et al. [30] reported that treatment of
macrophages with GS in vitro increased markers of M2 polarization in RAW264.7 cells, primary mouse
macrophages, and human monocytes. M2 polarization of colonic macrophages was also found in vivo.
A shift away from the M1 phenotype in RAW264.7 cells have also been reported in other work [22,31],
and together, is supportive of the findings in the current study and the potential for GS to induce
beiging through stimulation of resident macrophages.
M2 macrophage polarization occurs during the Th2 response, is activated by IL-4 and
glucocorticoids, and release cytokines such as transforming growth factor-β (TGF-β) which can
orchestrate the tissue remodeling process. M2 polarization, purportedly as a result of IL-4 stimulation,
may also increase norepinephrine production and release [32]. It is hypothesized that cold-induced
sympathetic nervous system stimulation induces tyrosine hydroxylase enzyme activity in macrophages,
thereby increasing norepinephrine release capable of white adipose tissue beiging. This response has
been demonstrated in several rodent models [12], however additional work has recently questioned
the relevance of alternatively activated macrophages in adipose tissue [33]. In Fischer et al.,
macrophage-specific knockout of tyrosine hydroxylase had no impact on body temperature during
a cold challenge [33]. Further, in vitro IL-4 stimulation of bone marrow-derived macrophages also
failed to induce an adipocyte thermogenic profile in conditioned media experiments, and in vivo IL-4
Medicines 2019, 6, 22 11 of 14
treatment failed to increase energy expenditure in mice. This is in conflict with the findings in the
current study, however, the discrepancies may be related to differences in methodology.
The current study utilized the 3T3-L1 adipocyte line with a differentiation media that contained
thyroid hormone, which is important for producing an adipocyte sensitive to UCP1 upregulation [23].
Unlike the aforementioned study by Fischer et al. (2017), which only cultured for 24 h [33], adipocytes
in the current study were cultured in the conditioned media for 48 h. The additional time in a primed
cell may partially explain our results. Further, it is plausible that continued direct GS signaling
from the macrophage-media source may have contributed to the observed UCP1 upregulation.
Thus, it is reasonable to hypothesize that it may be necessary to have both systemic and resident
macrophage-directed adrenergic signaling to stimulate adipocytes. Lastly, the studies in Fischer et al.,
failed to see changes in metabolic outputs in mice with deficiencies in either tyrosine hydroxylase or
IL-4 [33]. In fact, it may be that alternatively activated macrophages contribute, but are not a primary
factor to beiging in vivo. Obesity-related macrophage infiltration in the adipose tissue may further
add to this contribution, as what was recently shown in cultured adipocytes treated with conditioned
media from primary macrophages obtained from obese donors [34].
The pharmacologic translation of in vitro studies to in vivo remains a challenge in assessing the
efficacy of phytochemicals to act as attenuators of disease. In the current study, we used the trans
(E)-form of GS for dosing, which we have previously demonstrated has less lipolytic potential than the
cis (Z)-form [17]. However, the cis (Z)-form is more cytotoxic [17], which attributed to the selection of
the trans (E)-form herein as we wanted to avoid the confounding factor of cell death from influencing
the results. It remains plausible that these two isoforms may have differing potentials to beige in vitro,
and considering the rapid metabolism of GS in vivo, may also vary widely in a whole-body system.
The Cmax for GS is 0.3 µM in rats [35], hence an important limitation of the current study is the
supraphysiological doses used. Nonetheless, GS has demonstrated synergistic properties with other
phytochemcials such as genistein [18], which would permit for the plausibility of a photochemical
blend that contained more physiologic relevant concentrations. Furthermore, hypolipidemic and
anti-diabetic effects of GS were demonstrated in humans [36] and rodents [19] suggesting potential
beneficial effects of GS under in vivo conditions.
5. Conclusions
Herein, findings from this work demonstrate that the anti-obesity effects of GS include beiging of
adipocytes in vitro. GS has direct activity on 3T3-L1 adipocytes, inducing mitochondrial biogenesis and
an upregulation of UCP1 and cellular oxygen consumption, indicative of a beige phenotype. Further,
GS appears to have the capability of promoting adipocyte beiging through a macrophage-dependent
mechanism. In the current study, treatment with GS in RAW264.7 macrophages promoted M2
polarization and subsequent catecholamine release that was capable of upregulating UCP1 in 3T3-L1
adipocytes. While preliminary results indicate that GS-induced enhancement of beiging may be due to
both direct and indirect signaling in cultured adipocytes (summarized in Figure 7). Further studies are
required to demonstrate this phenomenon in vivo.
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